Semaglutide
Tier 1: $198 (0.25-1mg) | Tier 2: $272 (1.25-1.5mg) | Tier 3: $284 (1.75-2.5mg)
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. It reduces appetite, slows gastric emptying, and improves insulin sensitivity. Clinical trials show 15-20% average body weight loss over 68 weeks.
Interested in Semaglutide?
Our medical team will evaluate if this medication is right for you during your consultation.
Dosage & Administration
Weekly subcutaneous injections for 16-20+ weeks with gradual dose escalation. You cannot rush this. If you take too much too fast, the side effects will be significantly worse.
Dose range: 250 mcg (0.25mg) to 2,400 mcg (2.4mg) weekly with stepwise titration every 4 weeks. Starting dose depends on your history of use.
Important: Like any prescribed medication, dosing varies from person to person. Always follow the dosage prescribed by your healthcare provider. Optimize 360 personalizes every protocol based on your labs, symptoms, and goals.
Side Effects
- Nausea: Most common, especially during dose escalation. Usually resolves within 2-3 weeks at each dose level.
- Constipation/Diarrhea: GI changes are common initially.
- Injection Site Reactions: Redness, swelling — generally mild.
- Headache: Mild, temporary.
- Hypoglycemia Risk: When combined with insulin or sulfonylureas — less common with semaglutide alone.
Why Choose Optimize 360 for Semaglutide
- Prescribed and monitored by Dr. Steve Farmer — 30+ years in hormone medicine
- Comprehensive lab work before prescribing — we never guess
- Sourced from licensed U.S. compounding pharmacies
- Transparent pricing — the price above is what you pay, no hidden fees
- Telehealth available nationwide — medications shipped to your door
- Unlimited messaging with your provider throughout treatment
Get Started Today
No memberships. No referral needed. Schedule your consultation and we'll take it from there.
How Semaglutide Works
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, which is naturally released by the gut after eating. It works through multiple mechanisms: reducing appetite by acting on hunger centers in the brain (hypothalamus), slowing gastric emptying to increase satiety after meals, and enhancing insulin secretion while suppressing glucagon release to improve blood sugar control. Semaglutide has a half-life of approximately 7 days, allowing once-weekly dosing. It is the active ingredient in Ozempic (for diabetes) and Wegovy (for weight management).
Benefits & Clinical Evidence
The STEP clinical trial program established semaglutide as a breakthrough in medical weight management. STEP 1 showed an average weight loss of 14.9% over 68 weeks at the 2.4 mg dose. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in overweight/obese patients — the first weight loss medication to show cardiovascular mortality benefit. Additional studies show improvements in blood pressure, lipid profiles, inflammatory markers, sleep apnea severity, and quality of life. Semaglutide fundamentally changed the landscape of obesity treatment.
Who Is a Good Candidate?
Semaglutide is appropriate for adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. It is also indicated for type 2 diabetes management. Patients who have struggled to lose weight through diet and exercise alone — or who have lost weight but cannot maintain it — are good candidates. Semaglutide is not appropriate for patients with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, or a history of pancreatitis. A medical evaluation is required before starting therapy.
What to Expect: Treatment Timeline
Appetite reduction typically begins within the first week. Weight loss of 2-4% is common in the first month. Significant weight loss (10-15%) develops over 4-8 months. Maximum effects are typically achieved at 12-16 months. Semaglutide is injected subcutaneously once weekly, starting at 0.25 mg and titrating up monthly to the target dose. Slow titration is essential for tolerability. Lab work monitors metabolic improvements throughout treatment. Available at Optimize 360 from $198/month starting.
Side Effects & Safety
Gastrointestinal side effects are the most common: nausea (affecting ~40% initially), vomiting, diarrhea, constipation, and abdominal discomfort. These are typically worst during dose escalation and improve significantly over time. Eating smaller meals, avoiding high-fat foods, and following the slow titration schedule help minimize GI effects. Less common concerns include gallbladder events (associated with rapid weight loss), injection site reactions, and fatigue. Regular monitoring includes metabolic labs and assessment of nutritional adequacy as caloric intake decreases.
Frequently Asked Questions
A: Compounded semaglutide contains the same active molecule as brand-name products. It is produced by licensed US compounding pharmacies during periods of FDA-recognized drug shortage. The compounding process follows USP standards, though compounded medications are not individually FDA-approved. Optimize 360 sources exclusively from licensed, inspected compounding pharmacies.
A: Eat smaller, more frequent meals. Avoid greasy, fried, or heavy foods. Stay hydrated. Follow the dose titration schedule — don't increase too quickly. Many patients find that nausea is mild and temporary, resolving within the first few weeks at each dose level. Your provider can adjust your titration schedule if nausea is significant.
A: Yes. Semaglutide works well alongside TRT, female HRT, and peptide protocols. Weight loss can improve hormonal profiles — men may see reduced estrogen conversion, and women may experience improved metabolic markers. Your provider will coordinate your complete protocol to ensure all therapies work together optimally.
Also Available